A Phase 3 Multi-centre Randomised Placebo-controlled Study of Azithromycin in the Primary Prevention of Radiologically-defined Bronchiectasis in Infants With Cystic Fibrosis

Trial Profile

A Phase 3 Multi-centre Randomised Placebo-controlled Study of Azithromycin in the Primary Prevention of Radiologically-defined Bronchiectasis in Infants With Cystic Fibrosis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 May 2016

At a glance

  • Drugs Azithromycin (Primary)
  • Indications Bacterial infections; Bronchiectasis; Cystic fibrosis
  • Focus Therapeutic Use
  • Acronyms COMBATCF
  • Most Recent Events

    • 28 Apr 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2020.
    • 28 Apr 2016 Planned primary completion date changed from 1 Dec 2017 to 1 May 2020.
    • 16 May 2012 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top